1RKLB Fundamental Analysis - ROCKET LAB CORP

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to 1RKLB. 1RKLB was compared to 47 industry peers in the Aerospace & Defense industry. While 1RKLB seems to be doing ok healthwise, there are quite some concerns on its profitability. 1RKLB shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year 1RKLB has reported negative net income.

In the past year 1RKLB has reported a negative cash flow from operations.

1RKLB had negative earnings in each of the past 5 years.

1RKLB had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -16.46%, 1RKLB is not doing good in the industry: 91.49% of the companies in the same industry are doing better.

1RKLB has a Return On Equity of -47.89%. This is amonst the worse of the industry: 1RKLB underperforms 82.98% of its industry peers.

		Industry Rank	Sector Rank
ROA	-16.46%
ROE	-47.89%
ROIC	N/A

ROA(3y)-16.4%

ROA(5y)-18.08%

ROE(3y)-34.28%

ROE(5y)-34.08%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 27.30%, 1RKLB is in line with its industry, outperforming 51.06% of the companies in the same industry.

1RKLB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	27.3%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

1RKLB does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for 1RKLB has been increased compared to 1 year ago.

Compared to 5 years ago, 1RKLB has more shares outstanding

1RKLB has a worse debt/assets ratio than last year.

2.2 Solvency

1RKLB has an Altman-Z score of 15.69. This indicates that 1RKLB is financially healthy and has little risk of bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 15.69, 1RKLB belongs to the top of the industry, outperforming 97.87% of the companies in the same industry.

A Debt/Equity ratio of 0.97 indicates that 1RKLB is somewhat dependend on debt financing.

1RKLB has a Debt to Equity ratio of 0.97. This is in the lower half of the industry: 1RKLB underperforms 74.47% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.97
Debt/FCF	N/A
Altman-Z	15.69

ROIC/WACCN/A

WACC10.41%

2.3 Liquidity

1RKLB has a Current Ratio of 2.08. This indicates that 1RKLB is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of 1RKLB (2.08) is better than 85.11% of its industry peers.

1RKLB has a Quick Ratio of 1.72. This is a normal value and indicates that 1RKLB is financially healthy and should not expect problems in meeting its short term obligations.

1RKLB has a better Quick ratio (1.72) than 87.23% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.08
Quick Ratio	1.72

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

1RKLB shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.11%.

Looking at the last year, 1RKLB shows a very strong growth in Revenue. The Revenue has grown by 64.98%.

Measured over the past years, 1RKLB shows a very strong growth in Revenue. The Revenue has been growing by 55.23% on average per year.

EPS 1Y (TTM)-8.11%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-33.33%

Revenue 1Y (TTM)64.98%

Revenue growth 3Y91.41%

Revenue growth 5Y55.23%

Sales Q2Q%32.13%

3.2 Future

The Earnings Per Share is expected to grow by 33.11% on average over the next years. This is a very strong growth

Based on estimates for the next years, 1RKLB will show a very strong growth in Revenue. The Revenue will grow by 38.99% on average per year.

EPS Next Y-10.68%

EPS Next 2Y25.56%

EPS Next 3Y33.11%

EPS Next 5YN/A

Revenue Next Year32.37%

Revenue Next 2Y43.11%

Revenue Next 3Y40.24%

Revenue Next 5Y38.99%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

1RKLB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year 1RKLB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as 1RKLB's earnings are expected to grow with 33.11% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y25.56%

EPS Next 3Y33.11%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

1RKLB does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ROCKET LAB CORP

BIT:1RKLB (7/24/2025, 7:00:00 PM)

41.695

+0.51 (+1.24%)

Chartmill FA Rating

GICS SectorIndustrials

GICS IndustryGroupCapital Goods

GICS IndustryAerospace & Defense

Earnings (Last)05-08 2025-05-08/amc

Earnings (Next)08-06 2025-08-06/amc

Inst Owners53.86%

Inst Owner ChangeN/A

Ins Owners0.65%

Ins Owner ChangeN/A

Market Cap19.24B

Analysts80.95

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)5.99%

Min EPS beat(2)3.88%

Max EPS beat(2)8.09%

EPS beat(4)4

Avg EPS beat(4)11.76%

Min EPS beat(4)3.88%

Max EPS beat(4)22.86%

EPS beat(8)7

Avg EPS beat(8)8.72%

EPS beat(12)8

Avg EPS beat(12)2.37%

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-0.8%

Min Revenue beat(2)-0.99%

Max Revenue beat(2)-0.61%

Revenue beat(4)1

Avg Revenue beat(4)-0.59%

Min Revenue beat(4)-1.23%

Max Revenue beat(4)0.46%

Revenue beat(8)1

Avg Revenue beat(8)-2.06%

Revenue beat(12)5

Avg Revenue beat(12)0.14%

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)0%

EPS NQ rev (3m)N/A

EPS NY rev (1m)-1.9%

EPS NY rev (3m)N/A

Revenue NQ rev (1m)0.09%

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-0.06%

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	48.53
P/FCF	N/A
P/OCF	N/A
P/B	52.44
P/tB	74.38
EV/EBITDA	N/A

EPS(TTM)-0.34

EYN/A

EPS(NY)-0.13

Fwd EYN/A

FCF(TTM)-0.33

FCFYN/A

OCF(TTM)-0.19

OCFYN/A

SpS0.86

BVpS0.8

TBVpS0.56

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-16.46%
ROE	-47.89%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	27.3%
FCFM	N/A

ROA(3y)-16.4%

ROA(5y)-18.08%

ROE(3y)-34.28%

ROE(5y)-34.08%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0.37

Health

		Industry Rank	Sector Rank
Debt/Equity	0.97
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	224.95%
Cap/Sales	16.44%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.08
Quick Ratio	1.72
Altman-Z	15.69

F-Score4

WACC10.41%

ROIC/WACCN/A

Cap/Depr(3y)174.96%

Cap/Depr(5y)206.2%

Cap/Sales(3y)19.28%

Cap/Sales(5y)34.12%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-8.11%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-33.33%

EPS Next Y-10.68%

EPS Next 2Y25.56%

EPS Next 3Y33.11%

EPS Next 5YN/A

Revenue 1Y (TTM)64.98%

Revenue growth 3Y91.41%

Revenue growth 5Y55.23%

Sales Q2Q%32.13%

Revenue Next Year32.37%

Revenue Next 2Y43.11%

Revenue Next 3Y40.24%

Revenue Next 5Y38.99%

EBIT growth 1Y-17.67%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year61.27%

EBIT Next 3Y42.3%

EBIT Next 5Y31.66%

FCF growth 1Y-14.69%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y4.79%

OCF growth 3YN/A

OCF growth 5YN/A

ROCKET LAB CORP (1RKLB.MI) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens